A Study to Evaluate the Mass Balance of [14C] HRS-5965 in Healthy Adult Male Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 3, 2024

Primary Completion Date

October 8, 2024

Study Completion Date

October 8, 2024

Conditions

Complement Mediated Primary or Secondary Glomerular Diseases

Interventions

DRUG

[14C] HRS-5965

Patients will receive single dose of orally \[14C\] HRS-5965 on Day 1.

Trial Locations (1)

The First Affiliated Hospital Of Shandong First Medical University（Shandong Provincial Qianfoshan Hospital）, Jinan

All Listed Sponsors

lead

Chengdu Suncadia Medicine Co., Ltd.

INDUSTRY

NCT06567392 - A Study to Evaluate the Mass Balance of [14C] HRS-5965 in Healthy Adult Male Volunteers | Biotech Hunter | Biotech Hunter